KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Depreciation & Amortization (CF): 2009-2024

Historic Depreciation & Amortization (CF) for Novavax (NVAX) over the last 16 years, with Dec 2024 value amounting to $48.5 million.

  • Novavax's Depreciation & Amortization (CF) fell 48.15% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.0 million, marking a year-over-year decrease of 25.16%. This contributed to the annual value of $48.5 million for FY2024, which is 17.64% up from last year.
  • As of FY2024, Novavax's Depreciation & Amortization (CF) stood at $48.5 million, which was up 17.64% from $41.2 million recorded in FY2023.
  • Over the past 5 years, Novavax's Depreciation & Amortization (CF) peaked at $48.5 million during FY2024, and registered a low of $4.9 million during FY2020.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $41.2 million (2023), whereas its average is $39.6 million.
  • Per our database at Business Quant, Novavax's Depreciation & Amortization (CF) fell by 13.94% in 2020 and then soared by 159.18% in 2021.
  • Yearly analysis of 5 years shows Novavax's Depreciation & Amortization (CF) stood at $4.9 million in 2020, then skyrocketed by 159.18% to $12.7 million in 2021, then skyrocketed by 129.48% to $29.1 million in 2022, then surged by 41.89% to $41.2 million in 2023, then climbed by 17.64% to $48.5 million in 2024.